Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis

NCT02186171 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02186171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02186171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
June 16, 2014
Completion date
April 20, 2016
Enrollment
245 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis in men